HKEX Filings
-
Jul 19, 2022
GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
-
Jul 4, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended June 30, 2022
-
Jun 27, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATES STRONG CROSS-NEUTRALIZATION AGAINST OMICRON AS A HOMOLOGOUS BOOSTER
-
Jun 20, 2022LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
-
Jun 20, 2022APPOINTMENT OF NON-EXECUTIVE DIRECTORS
-
Jun 14, 2022VOLUNTARY ANNOUNCEMENT - CLOVER DOSES FIRST PATIENT WITH SCB-219M IN PHASE 1 TRIAL FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
-
Jun 14, 2022VOLUNTARY ANNOUNCEMENT - CLOVER DOSES FIRST PARTICIPANTS IN PHASE 3 TRIAL EVALUATING SCB-2019 AS A HETEROLOGOUS COVID-19 BOOSTER FOLLOWING PRIOR VACCINATION WITH INACTIVATED, MRNA OR VIRAL VECTOR VACCINES
-
Jun 7, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended May 31, 2022
-
Jun 5, 2022INSIDE INFORMATION - BUSINESS UPDATE
-
May 31, 2022VOLUNTARY ANNOUNCEMENT - CLOVER DOSES FIRST PARTICIPANTS IN PHASE I TRIAL WITH SCB-2020S, A POTENTIALLY BROADLY PROTECTIVE CHIMERIC COVID-19 VACCINE CANDIDATE
-
May 27, 2022Fourth Amended and Restated Memorandum and Articles of Association
-
May 27, 2022POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 27, 2022
-
May 12, 2022GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
-
May 5, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S BIVALENT COVID-19 VACCINE CANDIDATE DEMONSTRATES BROAD NEUTRALIZATION AGAINST OMICRON AND OTHER VARIANTS OF CONCERN
-
May 5, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended April 30, 2022
-
Apr 22, 2022LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
-
Apr 22, 2022RESIGNATION OF A NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE
-
Apr 21, 2022FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
-
Apr 21, 2022NOTICE OF ANNUAL GENERAL MEETING
-
Apr 21, 2022(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED GRANTING OF OPTIONS; (3) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (4) PROPOSED RE-APPOINTMENT OF AUDITOR; (5) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; AND (6) NOTICE OF ANNUAL GENERAL MEETING
